We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Eficacy and Safety of Systemic Treatments for Psoriasis in Elderly Patients.
- Authors
PIASERICO, Stefano; CONTI, Andrea; LO CONSOLE, Francesco; DE SIMONE, Clara; PRESTINARI, Francesca; MAZZOTTA, Annamaria; GUALDI, Giulio; GUARNERI, Claudio; BORSARI, Stefania; CASSANO, Nicoletta
- Abstract
Management of psoriasis in elderly patients can be chalenging, because of the impairment of immune system eficiency and the presence of comorbidities that contraindicate systemic therapies. We studied the safety and eficacy of systemic traditional and biological treatments in 187 consecutive psoriatic patients aged > 65 years. At week 12 of therapy, Psoriasis Area and Severity Index 75 was achieved by 49%, 27%, 46% and 31% of patients who received methotrexate, acitretin, cyclosporine or PUVA, and 64%, 65%, 93%, 57% and 100% of patients who received etanercept, adalimumab, inliximab, efalizumab and ustekinumab. The rate of adverse events was 0.12, 0.32, 1.4 and 0.5 per patient-year in the methotrexate, acitretin, cyclosporine and PUVA groups and 0.11, 0.35, 0.19, 0.3 and 0.26 in the etanercept, adalimumab, inliximab, efalizumab and ustekinumab groups. Traditional drugs were less effective than biologics in our elderly population. Etanercept was associated with a lower rate of adverse events compared with other treatments.
- Publication
Acta Dermato-Venereologica, 2014, Vol 94, Issue 3, p293
- ISSN
0001-5555
- Publication type
Academic Journal
- DOI
10.2340/00015555-1719